HIT-CF, a European Union-funded research project, is working to provide personalized disease-modifying treatments to cystic fibrosis (CF) patients with rare CFTR mutations who lack effective treatment options. ӗe hope that within five years, these patients will have new drugs,ԠKors van der Ent, MD, PhD, professor in pediatric pulmonology at the University Medical Centre in [ŝThe post Personalized Medicines for Rare Mutations Are Focus of HIT-CF in EU appeared first on Cystic Fibrosis News Today
